医学
肾脏疾病
内科学
入射(几何)
危险系数
倾向得分匹配
队列
比例危险模型
队列研究
质子抑制剂泵
肾
泌尿科
急性肾损伤
风险因素
风险评估
低风险
回顾性队列研究
相对风险
肾功能
药物流行病学
胃肠病学
前瞻性队列研究
肾病科
重症监护医学
疾病
作者
Su Young Kim,Hyun-Soo Kim,Tae Sic Lee,Sangwon Hwang,Jun Young Lee
摘要
BACKGROUND AND HYPOTHESIS: Proton pump inhibitors (PPIs) are widely used for acid suppression but have been associated with kidney injury. Potassium-competitive acid blockers (P-CABs) such as tegoprazan provide rapid, reversible inhibition of gastric H⁺/K⁺-ATPase, yet their renal safety remains unclear. We compared the risk of incident chronic kidney disease (CKD) between tegoprazan and PPIs in a nationwide population-based cohort. METHODS: Using the Korean Health Insurance Review and Assessment database, we identified adults without prior kidney disease who initiated tegoprazan or a PPI during 2020-2021. After 1:3 propensity score matching, we compared the risk of incident CKD using Cox proportional hazards models. Sensitivity and subgroup analyses examined robustness and effect modification by age, sex, and comorbidities. RESULTS: Among 901,606 new users (43,864 tegoprazan; 857,742 PPIs), PPI use was associated with a higher CKD incidence (6.16 vs 4.63 per 1,000 person-years). In the matched cohort, PPI initiation was associated with a higher risk of CKD than tegoprazan initiation (hazard ratio 1.22; 95% CI 1.09-1.37; P < 0.01). Findings were consistent across subgroups and sensitivity analyses, including the unmatched cohort (HR 1.34; 95% CI 1.20-1.48; P < 0.01). CONCLUSION: In this large real-world analysis, PPI initiation was associated with a higher rate of newly coded CKD than tegoprazan initiation. These findings provide comparative kidney safety data and suggest that risk of kidney injury may be one consideration, alongside efficacy and cost, when prolonged acid suppression is required.
科研通智能强力驱动
Strongly Powered by AbleSci AI